Long-term vemurafenib therapy in advanced melanoma patients: cutaneous toxicity and prognostic implications-Reference-Cited by-同舟云学术

Long-term vemurafenib therapy in advanced melanoma patients: cutaneous toxicity and prognostic implications

Published:2020-09-09 Issue: Volume: Page:1-8
ISSN:0954-6634
Container-title:Journal of Dermatological Treatment
language:en
Short-container-title:Journal of Dermatological Treatment

Author:

Mandel Victor Desmond¹²^ORCID,Medri Matelda¹,Manganoni Ausilia Maria³,Pavoni Laura³,De Rosa Francesco⁴,Ribero Simone⁵^ORCID,Foca Flavia⁶^ORCID,Andreis Daniele⁶^ORCID,Mazzoni Laura¹,Magi Serena¹,Farnetani Francesca⁷^ORCID,Palla Marco⁸^ORCID,Ulivi Paola⁹^ORCID,Stanganelli Ignazio¹²

Affiliation:

1. Skin Cancer Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Meldola, Italy

2. Dermatology Unit, Department of Clinical and Experimental Medicine, University of Parma, Parma, Italy

3. Department of Dermatology, Spedali Civili di Brescia, Brescia, Italy

4. Immunotherapy, Cell Therapy and Biobank, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Meldola, Italy

5. Dermatologic Clinic, Department of Medical Sciences, University of Turin, Turin, Italy

6. Unit of Biostatistics and Clinical Trials, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Meldola, Italy

7. Dermatology Unit, Surgical, Medical and Dental Department of Morphological Sciences related to Transplant, Oncology and Regenerative Medicine, University of Modena and Reggio Emilia, Modena, Italy

8. Unit of Melanoma, Cancer Immunotherapy & Innovative Therapies Unit, Istituto Nazionale Tumori “Fondazione G. Pascale”, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Naples, Italy

9. Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Meldola, Italy

Publisher

Informa UK Limited

Subject

Dermatology

Link

https://www.tandfonline.com/doi/pdf/10.1080/09546634.2020.1817838

Reference18 articles.

1. Prognostic and Clinicopathologic Associations of Oncogenic BRAF in Metastatic Melanoma

2. Survival of patients with advanced metastatic melanoma: the impact of novel therapies–update 2017

3. Off-label use of targeted therapies in oncology

4. Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

5. Vemurafenib in patients with BRAFV600 mutated metastatic melanoma: an open-label, multicentre, safety study

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. BRAF and MEK Inhibitors and Their Toxicities: A Meta-Analysis;Cancers;2022-12-26

2. Vemurafenib;Reactions Weekly;2022-07